Sign in
PTPI Stock Price, Chart, Stats & News
Petros Pharmaceuticals, Inc.
Save
186,961
Market cap
–
Current P/E
–
Forward P/E
PTPI chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 63.50% |
Operating margin | -1844.61% |
Pretax margin | -1852.35% |
Net margin | -968.20% |
Effective tax rate | – |
ROA | -114.51% |
ROE | 304.15% |
D/E | – |
Interest coverage ratio | -79.91x |
PTPI valuation
P/E | – |
P/S | 0.26x |
P/B | 0.08x |
P/CF | -0.05x |
P/FCF | -0.04x |
P/OCF | -0.05x |
PEG | -0.00x |
EV multiple | -0.53x |
About
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease.
Similar securities
Based on sector and market capitalization
Report issue